We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.

Breast Radiation Score

To further improve outcomes and reduce unnecessary treatment for breast cancer patients, Exact Sciences is developing a genomic test designed to evaluate the activity of 16 cancer genes with the goal of determining benefit from radiation therapy after breast-conserving surgery. The gene expression signature developed by PFS Genomics, a company Exact Sciences acquired in early 2021, addresses a major clinical need: identifying which women with early-stage breast cancer need radiotherapy and which do not. Being able to provide women with a clear answer to this question has the potential to minimize over- or under-treatment and allow women to further personalize their breast cancer treatment plans.